JP2011510080A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510080A5
JP2011510080A5 JP2010544359A JP2010544359A JP2011510080A5 JP 2011510080 A5 JP2011510080 A5 JP 2011510080A5 JP 2010544359 A JP2010544359 A JP 2010544359A JP 2010544359 A JP2010544359 A JP 2010544359A JP 2011510080 A5 JP2011510080 A5 JP 2011510080A5
Authority
JP
Japan
Prior art keywords
membered
nitrogen
sulfur
oxygen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010544359A
Other languages
English (en)
Japanese (ja)
Other versions
JP5581219B2 (ja
JP2011510080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000513 external-priority patent/WO2009094224A1/en
Publication of JP2011510080A publication Critical patent/JP2011510080A/ja
Publication of JP2011510080A5 publication Critical patent/JP2011510080A5/ja
Application granted granted Critical
Publication of JP5581219B2 publication Critical patent/JP5581219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010544359A 2008-01-25 2009-01-26 チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用 Active JP5581219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6243908P 2008-01-25 2008-01-25
US61/062,439 2008-01-25
PCT/US2009/000513 WO2009094224A1 (en) 2008-01-25 2009-01-26 Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors

Publications (3)

Publication Number Publication Date
JP2011510080A JP2011510080A (ja) 2011-03-31
JP2011510080A5 true JP2011510080A5 (enExample) 2013-03-07
JP5581219B2 JP5581219B2 (ja) 2014-08-27

Family

ID=40637132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010544359A Active JP5581219B2 (ja) 2008-01-25 2009-01-26 チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用

Country Status (4)

Country Link
US (1) US9029411B2 (enExample)
EP (1) EP2250160B1 (enExample)
JP (1) JP5581219B2 (enExample)
WO (1) WO2009094224A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
KR20110018451A (ko) * 2008-06-19 2011-02-23 밀레니엄 파머슈티컬스 인코퍼레이티드 티오펜 또는 티아졸 유도체, 그리고 ｐｉ3ｋ 저해물질로서 이들의 용도
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
EP2391619A1 (en) 2009-01-30 2011-12-07 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
PL2368890T3 (pl) 2009-06-11 2013-10-31 Abbvie Bahamas Ltd Inhibitory wirusa zapalenia wątroby C
NZ597983A (en) * 2009-08-20 2014-05-30 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG10201506238SA (en) 2010-08-11 2015-09-29 Millennium Pharm Inc Heteroaryls And Uses Thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PE20141044A1 (es) 2010-10-13 2014-09-07 Millennium Pharm Inc Heteroarilos y sus usos
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
BR112014016930A8 (pt) 2012-01-11 2017-12-26 Bayer Ip Gmbh compostos tetrazol-5-il- e triazol-5-il-arila e uso destes como herbicidas
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
DK3418275T3 (da) * 2016-02-16 2021-05-10 Korea Inst Sci & Tech Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer
WO2019016393A1 (en) 2017-07-21 2019-01-24 Antabio Sas CHEMICAL COMPOUNDS

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE581861A (enExample) 1958-08-20
US3852293A (en) 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
US3821384A (en) 1972-10-06 1974-06-28 Uniroyal Inc Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same
DE3021590A1 (de) 1980-06-09 1981-12-17 Hoechst Ag, 6000 Frankfurt 4-halogen-5-(halogenmethyl-phenyl)-oxazol-derivate, ein verfahren zu ihrer herstellung und sie enthaltenden strahlungsempfindliche massen
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU4618497A (en) 1996-08-27 1998-03-19 Novartis Ag Herbicidal s-substituted 1,2,4,6-thiatriazines
JPH1087490A (ja) 1996-09-10 1998-04-07 Sagami Chem Res Center インターロイキン６生産抑制剤、骨吸収抑制剤、抗骨粗鬆症剤、及びチアゾール化合物
PT853083E (pt) 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
WO1998047894A1 (en) 1997-04-24 1998-10-29 Dow Agrosciences Llc Pesticidal 3-(substituted phenyl)-5-(thienyl or furyl)-1,2,4-triazoles
JP2002520324A (ja) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド 新規な血管形成インヒビター
DE19858192A1 (de) 1998-12-17 2000-06-21 Aventis Cropscience Gmbh 4-Trifluormethyl-3-oxazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
WO2001052845A1 (en) 2000-01-18 2001-07-26 Vertex Pharmaceuticals Incorpoated Gyrase inhibitors and uses thereof
EP1389206B1 (en) 2001-04-13 2006-09-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
DE60227794D1 (de) 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
HRP20040098B1 (en) 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
ES2309207T3 (es) 2001-09-05 2008-12-16 Smithkline Beecham Plc Derivados furanicos sustituidos con piridina como inhibidores de quinasa raf.
US20040198773A1 (en) 2001-09-26 2004-10-07 Barry Hart Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
WO2003027105A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
GEP20074171B (en) 2001-11-08 2007-07-25 Elan Pharm Inc N,n'−substituted−1,3−diamino−2−hydroxypropane derivatives
CA2493908A1 (en) 2002-08-08 2004-02-19 Smithkline Beecham Corporation Thiophene compounds
US20050004122A1 (en) 2002-08-14 2005-01-06 Brown Bradley B. Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
ATE411996T1 (de) 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7122560B2 (en) 2003-06-18 2006-10-17 Bristol-Myers Squibb Company Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
WO2005058884A2 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
WO2005075470A1 (en) 2004-01-28 2005-08-18 Smithkline Beecham Corporation Thiazole compounds
JP2007519753A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
CN1989131A (zh) 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
CA2565965A1 (en) * 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
WO2006068933A2 (en) 2004-12-21 2006-06-29 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
GB0503962D0 (en) 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
KR20070108916A (ko) 2005-02-25 2007-11-13 쿠도스 파마슈티칼스 리미티드 Ｍｔｏｒ 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도
CN1834095B (zh) 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
US7612067B2 (en) 2005-03-21 2009-11-03 Eli Lilly And Company Imidazopyridazine compounds
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
JP2007197324A (ja) 2006-01-23 2007-08-09 Toray Ind Inc ２，４，５−置換−１，３−アゾール誘導体
CN101374808B (zh) 2006-01-24 2011-05-25 伊莱利利公司 孕酮受体的吲哚磺酰胺调节剂
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
UA94097C2 (ru) 2006-03-27 2011-04-11 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
CN101484452A (zh) 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
CN101484447A (zh) 2006-05-23 2009-07-15 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的噻吩-甲酰胺类
WO2007138110A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7985860B2 (en) 2006-08-14 2011-07-26 Schering Corporation Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives
WO2008024980A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
BRPI0720057A2 (pt) 2006-12-04 2013-12-17 Astrazeneca Ab Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de inibição de girase bacteriana de dna e/ou topoisomerase iv bacteriana em um animal de sangue quente, de produção de um efeito antibacteriano em um animal de sangue quente e de tratamento de uma infecção bacteriana em um animal de sangue quente, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
CA2677264C (en) 2007-02-02 2021-11-30 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
JP5363997B2 (ja) 2007-02-07 2013-12-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害剤
CN101687787A (zh) 2007-04-30 2010-03-31 健泰科生物技术公司 Iap的抑制剂
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
WO2008157273A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
EP2207778A2 (en) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
ES2399774T3 (es) 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
GB0805818D0 (en) 2008-03-31 2008-04-30 Ucb Pharma Sa Therapeutic agents
KR20110018451A (ko) 2008-06-19 2011-02-23 밀레니엄 파머슈티컬스 인코퍼레이티드 티오펜 또는 티아졸 유도체, 그리고 ｐｉ3ｋ 저해물질로서 이들의 용도
WO2009158374A2 (en) 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibitors of akt activity
GB0812309D0 (en) 2008-07-03 2008-08-13 Ucb Pharma Sa Therapeutic agents
JP2011527680A (ja) 2008-07-09 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション Ｊａｎｕｓキナーゼの阻害剤
JP5698666B2 (ja) 2008-08-04 2015-04-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆａａｈの阻害剤として有用なオキサゾール誘導体
US8586582B2 (en) 2008-11-11 2013-11-19 Xcovery Holding Company, Llc PI3K/mTOR kinase inhibitors
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8575150B2 (en) 2008-12-16 2013-11-05 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of Alzheimer's disease
CN102256972A (zh) 2008-12-18 2011-11-23 霍夫曼-拉罗奇有限公司 噻唑基-苯并咪唑类
WO2010080873A1 (en) 2009-01-08 2010-07-15 Glaxo Group Limited Oxazoles as modulators of chemokine receptors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP2391619A1 (en) 2009-01-30 2011-12-07 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2012526836A (ja) 2009-05-13 2012-11-01 アムジエン・インコーポレーテツド Ｐｉｋｋ阻害薬としてのヘテロアリール化合物
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG10201506238SA (en) 2010-08-11 2015-09-29 Millennium Pharm Inc Heteroaryls And Uses Thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PE20141044A1 (es) 2010-10-13 2014-09-07 Millennium Pharm Inc Heteroarilos y sus usos
WO2013096642A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof

Similar Documents

Publication Publication Date Title
JP2011510080A5 (enExample)
TWI332832B (en) Method for modulating calcium ion-release-activated calcium ion channels
JP2011524904A5 (enExample)
JP2015506347A5 (enExample)
JP2013536193A5 (enExample)
JP2015503505A5 (enExample)
HRP20161306T1 (hr) Dimerni spojevi kao agonisti receptora fgf (fgfr), postupak za njihovu pripravu i njihova terapijska uporaba
JP2014521653A5 (enExample)
DK3009426T3 (en) 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICINE COMPREHENSIVE AS AN ACTIVE INGREDIENT
JP2015503504A5 (enExample)
JP2008513508A (ja) 炎症及び免疫に関連する用途に用いる化合物
JP2012505234A5 (enExample)
JP2013533318A5 (enExample)
JP2019529444A5 (enExample)
JP2008513498A5 (enExample)
JP2017502092A5 (enExample)
JP2005508967A5 (enExample)
RU2009125578A (ru) Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний
JP2014525426A5 (enExample)
JP2007517895A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2007505044A5 (enExample)
EP3817815A1 (en) Nlrp modulators
RU2008108516A (ru) 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ
CN101223139B (zh) 3-氨基咔唑化合物、包含该化合物的药物组合物及其制备方法